Legend Biotech logo

Legend BiotechNASDAQ: LEGN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 June 2020

Next earnings report:

11 March 2025

Last dividends:

N/A

Next dividends:

N/A
$7.44 B
-46%vs. 3y high
91%vs. sector
-vs. 3y high
-vs. sector
-81%vs. 3y high
87%vs. sector
-89%vs. 3y high
82%vs. sector

Price

regular market | 1 min ago
$40.58+$2.13(+5.53%)

Dividend

No data over the past 3 years
$160.21 M$185.68 M
$160.21 M-$125.32 M

Analysts recommendations

Institutional Ownership

LEGN Latest News

Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript
seekingalpha.com12 November 2024 Sentiment: POSITIVE

Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Mythili Koneru - Chief Medical Officer Steve Gavel - Senior Vice President, Commercial Development, U.S. & Europe Conference Call Participants Gena Wang - Barclays Kelly Shi - Jefferies Jessica Fye - JPMorgan Kostas Biliouris - BMO Capital James Shin - DB Vikram Purohit - Morgan Stanley Mitchell Kapoor - H.C. Wainright Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Operator Ladies and gentlemen, thank you for standing by.

Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com12 November 2024 Sentiment: POSITIVE

Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
zacks.com11 November 2024 Sentiment: POSITIVE

After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
globenewswire.com05 November 2024 Sentiment: POSITIVE

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma

Legend Biotech Appoints Alan Bash as President of CARVYKTI®
globenewswire.com04 November 2024 Sentiment: POSITIVE

Newly created position to lead efforts focused on continued growth and sales Newly created position to lead efforts focused on continued growth and sales

Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade
zacks.com24 October 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
globenewswire.com03 October 2024 Sentiment: POSITIVE

New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
globenewswire.com27 September 2024 Sentiment: POSITIVE

SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 CARVYKTI® is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1 These results were presented as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65) in Rio de Janeiro, Brazil.1

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
seekingalpha.com18 September 2024 Sentiment: POSITIVE

Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged 60% YoY, reaching US$343 million in 1H2024, forecasting US$1 bilion+ for the full year. Rumors since July claim Legend Biotech faced a takeover bid, with fresh whispers of pricing disputes in negotiations this week.

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
globenewswire.com09 August 2024 Sentiment: POSITIVE

SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights.

  • 1(current)
  • 2

What type of business is Legend Biotech?

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.

What sector is Legend Biotech in?

Legend Biotech is in the Healthcare sector

What industry is Legend Biotech in?

Legend Biotech is in the Biotechnology industry

What country is Legend Biotech from?

Legend Biotech is headquartered in United States

When did Legend Biotech go public?

Legend Biotech initial public offering (IPO) was on 05 June 2020

What is Legend Biotech website?

https://www.legendbiotech.com

Is Legend Biotech in the S&P 500?

No, Legend Biotech is not included in the S&P 500 index

Is Legend Biotech in the NASDAQ 100?

No, Legend Biotech is not included in the NASDAQ 100 index

Is Legend Biotech in the Dow Jones?

No, Legend Biotech is not included in the Dow Jones index

When was Legend Biotech the previous earnings report?

No data

When does Legend Biotech earnings report?

The next expected earnings date for Legend Biotech is 11 March 2025